Giant Biogene Holding Co., Ltd.

SEHK:2367 Stock Report

Market Cap: HK$28.7b

Giant Biogene Holding Future Growth

Future criteria checks 2/6

Giant Biogene Holding is forecast to grow earnings and revenue by 11.7% and 12.3% per annum respectively. EPS is expected to grow by 10.7% per annum. Return on equity is forecast to be 18.8% in 3 years.

Key information

11.7%

Earnings growth rate

10.70%

EPS growth rate

Personal Products earnings growth15.0%
Revenue growth rate12.3%
Future return on equity18.80%
Analyst coverage

Good

Last updated12 Jun 2026

Recent future growth updates

Analysis Article Aug 29

Giant Biogene Holding Co., Ltd. (HKG:2367) Just Reported Earnings, And Analysts Cut Their Target Price

Shareholders might have noticed that Giant Biogene Holding Co., Ltd. ( HKG:2367 ) filed its interim result this time...
Analysis Article Mar 28

Giant Biogene Holding Co., Ltd. Just Beat Revenue Estimates By 5.3%

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) investors will be delighted, with the company turning in some strong...

Recent updates

Analysis Article May 06

Giant Biogene Holding's (HKG:2367) Sluggish Earnings Might Be Just The Beginning Of Its Problems

The subdued market reaction suggests that Giant Biogene Holding Co., Ltd.'s ( HKG:2367 ) recent earnings didn't contain...
Analysis Article Mar 24

Time To Worry? Analysts Are Downgrading Their Giant Biogene Holding Co., Ltd. (HKG:2367) Outlook

The analysts covering Giant Biogene Holding Co., Ltd. ( HKG:2367 ) delivered a dose of negativity to shareholders...
Analysis Article Sep 22

Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 31% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Giant Biogene Holding fair value estimate is HK$93.21 Current...
Analysis Article Aug 29

Giant Biogene Holding Co., Ltd. (HKG:2367) Just Reported Earnings, And Analysts Cut Their Target Price

Shareholders might have noticed that Giant Biogene Holding Co., Ltd. ( HKG:2367 ) filed its interim result this time...
Analysis Article Aug 11

We Ran A Stock Scan For Earnings Growth And Giant Biogene Holding (HKG:2367) Passed With Ease

SEHK:2367 1 Year Share Price vs Fair Value Explore Giant Biogene Holding's Fair Values from the Community and select...
Analysis Article Jun 22

The Price Is Right For Giant Biogene Holding Co., Ltd. (HKG:2367) Even After Diving 37%

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) shareholders won't be pleased to see that the share price has had a very...
Analysis Article May 29

Is There An Opportunity With Giant Biogene Holding Co., Ltd.'s (HKG:2367) 33% Undervaluation?

Key Insights The projected fair value for Giant Biogene Holding is HK$104 based on 2 Stage Free Cash Flow to Equity...
Analysis Article May 07

Why Investors Shouldn't Be Surprised By Giant Biogene Holding Co., Ltd.'s (HKG:2367) 29% Share Price Surge

Despite an already strong run, Giant Biogene Holding Co., Ltd. ( HKG:2367 ) shares have been powering on, with a gain...
Analysis Article May 06

Giant Biogene Holding's (HKG:2367) Solid Earnings May Rest On Weak Foundations

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) just released a solid earnings report, and the stock displayed some...
Analysis Article Mar 28

Giant Biogene Holding Co., Ltd. Just Beat Revenue Estimates By 5.3%

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) investors will be delighted, with the company turning in some strong...
Analysis Article Feb 06

What Is Giant Biogene Holding Co., Ltd.'s (HKG:2367) Share Price Doing?

Giant Biogene Holding Co., Ltd. ( HKG:2367 ), might not be a large cap stock, but it received a lot of attention from a...
Analysis Article Jan 14

Here's Why Giant Biogene Holding (HKG:2367) Has Caught The Eye Of Investors

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article Nov 20

Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Giant Biogene Holding is HK$97.69 based on 2 Stage Free Cash Flow to Equity...
Analysis Article Aug 21

Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) shareholders are probably feeling a little disappointed, since its shares...
Analysis Article Aug 09

Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article Jul 01

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 9x, you may consider...
Analysis Article Apr 17

Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Key Insights The projected fair value for Giant Biogene Holding is HK$67.25 based on 2 Stage Free Cash Flow to Equity...
Analysis Article Mar 28

Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 8x, you may consider...
Analysis Article Mar 27

Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Giant Biogene Holding Co., Ltd. ( HKG:2367 ) investors will be delighted, with the company turning in some strong...
Analysis Article Dec 24

Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article Oct 30

A Look At The Intrinsic Value Of Giant Biogene Holding Co., Ltd. (HKG:2367)

Key Insights The projected fair value for Giant Biogene Holding is HK$32.31 based on 2 Stage Free Cash Flow to Equity...
Analysis Article Mar 28

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Share Price Matching Investor Opinion

With a price-to-earnings (or "P/E") ratio of 40.7x Giant Biogene Holding Co., Ltd. ( HKG:2367 ) may be sending very...

Earnings and Revenue Growth Forecasts

SEHK:2367 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287,9542,5341,7972,52714
12/31/20277,0032,2362,1442,28417
12/31/20266,1541,9381,6342,22617
12/31/20255,5191,9151,3521,781N/A
9/30/20255,8152,0881,4131,807N/A
6/30/20256,1112,2611,4731,834N/A
3/31/20255,8252,1621,6341,938N/A
12/31/20245,5392,0621,7942,041N/A
9/30/20244,9991,9151,7321,959N/A
6/30/20244,4591,7681,6701,877N/A
3/31/20243,9921,6101,5451,762N/A
12/31/20233,5241,4521,4191,647N/A
9/30/20233,2551,2521,2181,480N/A
6/30/20232,9851,0521,0161,313N/A
3/31/20232,6758748971,122N/A
12/31/20222,364696778932N/A
12/31/20211,552809617692N/A
12/31/20201,190826758834N/A
12/31/2019957552571656N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2367's forecast earnings growth (11.7% per year) is above the savings rate (3%).

Earnings vs Market: 2367's earnings (11.7% per year) are forecast to grow slower than the Hong Kong market (12.6% per year).

High Growth Earnings: 2367's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2367's revenue (12.3% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

High Growth Revenue: 2367's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2367's Return on Equity is forecast to be low in 3 years time (18.8%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 09:43
End of Day Share Price 2026/06/15 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Giant Biogene Holding Co., Ltd. is covered by 21 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melinda HuBernstein
Ethan CuiBofA Global Research
Zhuonan XuChina International Capital Corporation Limited